CRANBURY, N.J., June 23, 2017 -- 1ST Constitution Bancorp (NASDAQ:FCCY), parent company of 1ST Constitution Bank, announced that its Board of Directors has declared a cash dividend of $0.05 per common share. The cash dividend will be paid on July 25, 2017 to all shareholders of record as of the close of business on July 3, 2017.
1ST Constitution Bancorp is a financial service organization headquartered in Cranbury, New Jersey, with approximately $1.0 billion in assets and $870 million in deposits. 1ST Constitution Bank provides financial services to retail, corporate and small business customers through its 18 branch banking offices located in Bergen, Middlesex, Monmouth, Mercer and Somerset Counties in New Jersey. For additional information about 1ST Constitution, visit our website at www.1STCONSTITUTION.com, or call 609-655-4500.
1ST Constitution Bancorp is traded on the Nasdaq Global Market under the trading symbol “FCCY” and can be accessed through the Internet at www.1STCONSTITUTION.com.
The foregoing contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not historical facts and include expressions about management’s confidence and strategies and management’s expectations about new and existing programs and products, relationships, opportunities, taxation, technology and market conditions. These statements may be identified by such forward-looking terminology as “expect,” “look,” “believe,” “anticipate,” “may,” “will,” or similar statements or variations of such terms. Actual results may differ materially from such forward-looking statements. Factors that may cause results to differ materially from such forward-looking statements include, but are not limited to, changes in the direction of the economy in New Jersey, the direction of interest rates, effective income tax rates, loan prepayment assumptions, continued levels of loan quality and origination volume, continued relationships with major customers including sources for loans, a higher level of net loan charge-offs and delinquencies than anticipated, bank regulatory rules, regulations or policies that restrict or direct certain actions, the adoption, interpretation and implementation of new or pre-existing accounting pronouncements, a change in legal and regulatory barriers including issues related to compliance with anti-money laundering and bank secrecy act laws, as well as the effects of general economic conditions and legal and regulatory barriers and structure. 1ST Constitution Bancorp assumes no obligation for updating any such forward-looking statements at any time, except as required by law.
CONTACT: Robert F. Mangano President & Chief Executive Officer (609) 655-4500 Stephen J. Gilhooly Senior Vice President, Treasurer & Chief Financial Officer (609) 655-4500


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Samsung Electronics Shares Jump on HBM4 Mass Production Report
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Amazon Explores AI Content Marketplace With Media Publishers
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



